TLR-004
Inflammatory Bowel Disease
PreclinicalActive
Key Facts
About Tilray
Tilray's mission is to be the world's leading cannabis-focused consumer branded goods and pharmaceutical company. Its key achievements include establishing one of the largest global footprints in cannabis cultivation and distribution, successfully merging with Aphria to create an industry leader, and building a clinical pipeline targeting serious conditions like glioblastoma and epilepsy. The company's strategy is to drive growth through its diversified portfolio—spanning cannabis, beverage alcohol, and wellness products—while investing in high-value pharmaceutical R&D to unlock long-term value from cannabinoid science.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Function-based Consortium for IBD | PharmaBiome | Pre-clinical |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| TEV-‘574 (TL1A Inhibitor) | Teva | Phase 3 |
| IBD Subclassification | Bio-Me | Research |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |
| Zymfentra™ | Celltrion | Marketed |
| AVTX-008 | Avalo Therapeutics | Preclinical |